| Autor: |
Henna‐Riikka Junlén, Kristina Sonnevi, Ola Lindén, Mats Hellström, Mariana Villegas Scivetti, Mikael Olsson, Ida Tufvesson, Ann‐Sofie Johansson, Björn Engelbrekt Wahlin |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
eJHaem, Vol 4, Iss 3, Pp 647-655 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2688-6146 |
| DOI: |
10.1002/jha2.696 |
| Popis: |
Abstract The treatment of splenic marginal zone lymphoma is debated: splenectomy (the old standard‐of‐care) is better than chemotherapy but maybe not better than rituximab‐containing treatment. We examined all 358 patients diagnosed with splenic marginal zone lymphoma in Sweden 2000–2020. The median overall survival was 11.0 years. The median age was 73 years; 61% were women. Age was the only independently prognostic clinical characteristic. Eighty‐six patients were started on wait‐and‐watch, 90 rituximab monotherapy, 47 rituximab‐chemotherapy, 88 splenectomy, 37 chemotherapy, and 10 both systemic therapy and splenectomy. Overall survival was inferior in patients treated with chemotherapy, but equal in patients treated with rituximab, rituximab‐chemotherapy and splenectomy. Patients treated with both systemic therapy and splenectomy showed good outcome, suggesting that surgery can be safely reserved for nonresponders. After adjustment for age, survival did not differ between patients started on wait‐and‐watch and those treated with splenectomy or rituximab‐containing therapy. Over time, rituximab use and survival increased in patients ≥73 years. This is, to our knowledge, the largest population‐based study of splenic marginal zone lymphoma patients treated with upfront rituximab. We conclude that wait‐and‐watch remains the most reasonable option in asymptomatic splenic marginal zone lymphoma patients. Symptomatic patients should be offered single‐agent rituximab in first line. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text